Accelerating drug discovery
through synchrotron-based structural biology research
serving the pharmaceutical industry.

The IMCA-CAT insertion device synchrotron beamline, designed with stateā€‘of-the-art equipment, is ideally suited for proprietary drug discovery research.

  • intense, stable, mini beam
  • auto diffraction rastering
  • collect-along-a-vector
  • shutterless, continuous-rotation
  • auto data collection & processing
  • fast, encrypted data transfer

Discovery and lead-optimization phases of drug development are significantly accelerated at IMCA-CAT with high quality, ultra fast data acquisition for pharmaceutical structural biology.
  • high-throughput
  • fragment screening
  • MAD/SAD phasing
  • small, weakly diffracting crystals
  • large macromolecular assemblies
  • membrane proteins

Each year, more than 15,000 structures are solved from data collected at the IMCA-CAT beamline.
  • proprietary experiments
  • guaranteed, frequent access
  • on-site, remote, mail-in
  • extremely productive
  • exceptionally reliable
  • highly efficient
  • outstanding quality